21:35 , Jul 12, 2019 |  BC Week In Review  |  Company News

First domestic company gets a first-in-class approval in China

China's National Medical Products Administration (NMPA) approved in May an NDA from Beijing Wenfeng Tianji Pharmaceuticals Co. Ltd. (Beijing, China) for tapinarof (DMVT-505, WBI-1001, benvitimod) to treat mild to moderate stable psoriasis vulgaris. The product...
00:29 , May 25, 2019 |  BC Extra  |  Financial News

New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero

In a week in which two biotechs went public and a third opted for a billion-dollar takeout instead of an IPO, five companies filed on Friday to list on NASDAQ in IPOs that could raise...
02:21 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

AACR moves in a myeloid direction

Myeloid cells are showing up everywhere at this year’s AACR conference, suggesting the research community is rapidly expanding the ways it can harness the cell types to improve cancer immunotherapy responses. One of those ways...
20:15 , Mar 25, 2019 |  BC Innovations  |  Distillery Techniques

AHR levels in tumors predict response to Keytruda and other anti-PD-1 therapies in NSCLC

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Tissue markers Tumor levels of AHR could help predict response to Keytruda pembrolizumab and other PD-1 inhibitors in NSCLC. In 37 patients treated with Keytruda, high tumor levels of AHR protein...
00:33 , Jan 25, 2019 |  BC Week In Review  |  Company News

Celgene bolsters immuno-metabolism, immune cell toolbox with Kyn, Obsidian deals

Partnerships with Boston area biotechs Kyn Therapeutics Inc. and Obsidian Therapeutics Inc. announced on Jan. 18 by Celgene Corp. (NASDAQ:CELG) indicate the big biotech is continuing to build its immuno-metabolism and immune cell therapy toolboxes...
00:30 , Jan 19, 2019 |  BC Extra  |  Company News

Celgene bolsters immuno-metabolism, immune cell toolbox with Kyn, Obsidian deals

Partnerships with Boston area biotechs Kyn Therapeutics Inc. and Obsidian Therapeutics Inc. announced late this week by Celgene Corp. (NASDAQ:CELG) indicate the big biotech is continuing to build its immuno-metabolism and immune cell therapy toolboxes...
23:40 , Dec 14, 2018 |  BioCentury  |  Emerging Company Profile

ExCellThera’s safer allogeneic transplants

ExCellThera Inc. is expanding cord blood into allogeneic stem cell transplants for cancer that have lower treatment-related mortality rates and GvHD incidence than competing technologies. Hematopoietic stem cell transplants (HSCTs) of unexpanded cord blood have...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
03:21 , Nov 17, 2018 |  BioCentury  |  Product Development

Betting Combos on Biomarkers

Despite lackluster monotherapy data at SITC from the latest tranche of immunotherapy candidates, drug developers are moving into combination trials with PD-1 and PD-L1 inhibitors based on biomarkers of pharmacodynamic activity. Results from the next...
18:48 , Nov 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Liver fibrosis Patient sample and mouse studies suggest antagonizing AHR or RORγT could help treat liver fibrosis. In liver tissue samples from hepatitis patients, levels of IL-17A and IL-22, which are positively regulated by...